DEVELOPMENT OF THERAPEUTIC AGENTS: THE MATERNAL - FETAL PERSPECTIVE

C. Gedeon; F. Garcia Bournissen; G. Koren

doi:10.1002/9780470571224.pse464

DEVELOPMENT OF THERAPEUTIC AGENTS: THE MATERNAL - FETAL PERSPECTIVE

C. Gedeon
, F. Garcia Bournissen
, G. Koren

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Our objective in this chapter will be to present the state of relevant research and to stimulate interest in research efforts aimed at developing selective drugs for use in pregnancy. The hope is to explore therapeutic strategies that can either reduce unnecessary fetal exposure to drugs required by the mother or, in some instances, reduce maternal exposure to drugs destined for fetal treatment.

Original language	English
Title of host publication	Pharmaceutical Sciences Encyclopedia
Pages	1-18
Number of pages	18
ISBN (Electronic)	9780470571224
DOIs	https://doi.org/10.1002/9780470571224.pse464
State	Published - 1 Jan 2010
Externally published	Yes

Keywords

Orphan Drug Act
atosiban
diclectin
glyburide (glibenclamide)
pregnancy

Access to Document

10.1002/9780470571224.pse464

Cite this

@inbook{c272e4b700b640c3aae4c23ae89d5a52,

title = "DEVELOPMENT OF THERAPEUTIC AGENTS: THE MATERNAL - FETAL PERSPECTIVE",

abstract = "Our objective in this chapter will be to present the state of relevant research and to stimulate interest in research efforts aimed at developing selective drugs for use in pregnancy. The hope is to explore therapeutic strategies that can either reduce unnecessary fetal exposure to drugs required by the mother or, in some instances, reduce maternal exposure to drugs destined for fetal treatment.",

keywords = "Orphan Drug Act, atosiban, diclectin, glyburide (glibenclamide), pregnancy",

author = "C. Gedeon and Bournissen, \{F. Garcia\} and G. Koren",

note = "Publisher Copyright: {\textcopyright} 2010 John Wiley \& Sons, Inc.",

year = "2010",

month = jan,

day = "1",

doi = "10.1002/9780470571224.pse464",

language = "אנגלית",

pages = "1--18",

booktitle = "Pharmaceutical Sciences Encyclopedia",

}

TY - CHAP

T1 - DEVELOPMENT OF THERAPEUTIC AGENTS

T2 - THE MATERNAL - FETAL PERSPECTIVE

AU - Gedeon, C.

AU - Bournissen, F. Garcia

AU - Koren, G.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Our objective in this chapter will be to present the state of relevant research and to stimulate interest in research efforts aimed at developing selective drugs for use in pregnancy. The hope is to explore therapeutic strategies that can either reduce unnecessary fetal exposure to drugs required by the mother or, in some instances, reduce maternal exposure to drugs destined for fetal treatment.

AB - Our objective in this chapter will be to present the state of relevant research and to stimulate interest in research efforts aimed at developing selective drugs for use in pregnancy. The hope is to explore therapeutic strategies that can either reduce unnecessary fetal exposure to drugs required by the mother or, in some instances, reduce maternal exposure to drugs destined for fetal treatment.

KW - Orphan Drug Act

KW - atosiban

KW - diclectin

KW - glyburide (glibenclamide)

KW - pregnancy

UR - https://www.scopus.com/pages/publications/105031318345

U2 - 10.1002/9780470571224.pse464

DO - 10.1002/9780470571224.pse464

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:105031318345

SP - 1

EP - 18

BT - Pharmaceutical Sciences Encyclopedia

ER -

DEVELOPMENT OF THERAPEUTIC AGENTS: THE MATERNAL - FETAL PERSPECTIVE

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this